The Board of Pharmacy has received notice of the product recall below. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

QuVa Pharma has become aware that Fresenius Kabi has recalled several lots of Ketorolac, which is used in one of our compounded products R.E.C.K. (Ropivacaine, Epinephrine, Clonidine, Ketorolac) 50 ml in Sodium Chloride - 60 ml BD syringe (Product Code: 70092-1433-50).

Therefore, QuVa Pharma Inc. is initiating a recall to the customer level for 21 lots of R.E.C.K. (Ropivacaine, Epinephrine, Clonidine, Ketorolac) 50 ml in Sodium Chloride - 60 ml BD syringe (Product Code: 70092-1433-50) that used the recalled material from Fresenius Kabi. This product is a compounded sterile product, and QuVa Pharma Inc. is registered as a 503B outsourcing facility with the FDA.

The QuVa Pharma process to compound this CSP involves dual filtration system consisting of a 0.45um polyethersulfone (PES) membrane filter followed by a 0.22um PES membrane filter. In addition, each syringe is checked for particulate matter during ILP. Therefore, it is not anticipated that any particulate matter will be in our final CSP. Furthermore, we have no reported complaints regarding particulate matter in this CSP. QuVa Pharma is instituting this recall in an abundance of caution.

All the lots were shipped from our Bloomsbury location.